KR20150084992A - 인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제 - Google Patents
인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제 Download PDFInfo
- Publication number
- KR20150084992A KR20150084992A KR1020157015531A KR20157015531A KR20150084992A KR 20150084992 A KR20150084992 A KR 20150084992A KR 1020157015531 A KR1020157015531 A KR 1020157015531A KR 20157015531 A KR20157015531 A KR 20157015531A KR 20150084992 A KR20150084992 A KR 20150084992A
- Authority
- KR
- South Korea
- Prior art keywords
- purin
- amino
- alkyl
- ethyl
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 Cc1ncnc2c1nc(**)[n]2 Chemical compound Cc1ncnc2c1nc(**)[n]2 0.000 description 5
- FTNJQNQLEGKTGD-UHFFFAOYSA-N C1Oc(cccc2)c2O1 Chemical compound C1Oc(cccc2)c2O1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- UYYCVBASZNFFRX-UHFFFAOYSA-N CC(C)NC1CCCCC1 Chemical compound CC(C)NC1CCCCC1 UYYCVBASZNFFRX-UHFFFAOYSA-N 0.000 description 1
- NQYOHADVLAXQSK-UHFFFAOYSA-N CCCN(CC(C1)Nc2ncnc3c2nc(-c2c(C)[n](CC)nc2)[n]3C)C1=O Chemical compound CCCN(CC(C1)Nc2ncnc3c2nc(-c2c(C)[n](CC)nc2)[n]3C)C1=O NQYOHADVLAXQSK-UHFFFAOYSA-N 0.000 description 1
- BAUNVYKWVMFPMN-UHFFFAOYSA-N CC[n]1c(Cl)nc2c1ncnc2Cl Chemical compound CC[n]1c(Cl)nc2c1ncnc2Cl BAUNVYKWVMFPMN-UHFFFAOYSA-N 0.000 description 1
- WSNVGRPHNBJPPP-JTQLQIEISA-N CC[n]1c(Cl)nc2c1ncnc2N[C@@H](CC1)CN1C(C1CC1)=O Chemical compound CC[n]1c(Cl)nc2c1ncnc2N[C@@H](CC1)CN1C(C1CC1)=O WSNVGRPHNBJPPP-JTQLQIEISA-N 0.000 description 1
- YSKHRCGNQFWRFM-UHFFFAOYSA-N CC[n]1c(ncnc2Cl)c2nc1 Chemical compound CC[n]1c(ncnc2Cl)c2nc1 YSKHRCGNQFWRFM-UHFFFAOYSA-N 0.000 description 1
- DNRLNZVPSBUEBO-AWEZNQCLSA-N CC[n]1c(ncnc2N[C@@H](CC3)CN3C(C3CC3)=O)c2nc1C(NCC1CC1)=O Chemical compound CC[n]1c(ncnc2N[C@@H](CC3)CN3C(C3CC3)=O)c2nc1C(NCC1CC1)=O DNRLNZVPSBUEBO-AWEZNQCLSA-N 0.000 description 1
- WJBNDQWFJGCNSU-LBPRGKRZSA-N CC[n]1c(ncnc2N[C@@H](CC3)CN3C(C3CC3)=O)c2nc1C(OCC)=O Chemical compound CC[n]1c(ncnc2N[C@@H](CC3)CN3C(C3CC3)=O)c2nc1C(OCC)=O WJBNDQWFJGCNSU-LBPRGKRZSA-N 0.000 description 1
- MTYPIBSGQRCYNF-UHFFFAOYSA-N CC[n]1ncc(-c([n]2C)nc3c2ncnc3Cl)c1C Chemical compound CC[n]1ncc(-c([n]2C)nc3c2ncnc3Cl)c1C MTYPIBSGQRCYNF-UHFFFAOYSA-N 0.000 description 1
- KALVXJODCOOLPE-UHFFFAOYSA-N CC[n]1ncc(-c([n]2C)nc3c2ncnc3NC(C2)CNC2=O)c1C Chemical compound CC[n]1ncc(-c([n]2C)nc3c2ncnc3NC(C2)CNC2=O)c1C KALVXJODCOOLPE-UHFFFAOYSA-N 0.000 description 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N Cc1ncnc(C)c1N Chemical compound Cc1ncnc(C)c1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N Clc1ncnc2c1nc[nH]2 Chemical compound Clc1ncnc2c1nc[nH]2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- JIMSBKAHGYGPLD-UHFFFAOYSA-N NC(C1)CNC1=O Chemical compound NC(C1)CNC1=O JIMSBKAHGYGPLD-UHFFFAOYSA-N 0.000 description 1
- QTYGXDUXIZLHGI-ZETCQYMHSA-N N[C@@H](CC1)CN1C(C1CC1)=O Chemical compound N[C@@H](CC1)CN1C(C1CC1)=O QTYGXDUXIZLHGI-ZETCQYMHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727392P | 2012-11-16 | 2012-11-16 | |
| US61/727,392 | 2012-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150084992A true KR20150084992A (ko) | 2015-07-22 |
Family
ID=50730542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157015531A Withdrawn KR20150084992A (ko) | 2012-11-16 | 2013-11-15 | 인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9938281B2 (enExample) |
| EP (1) | EP2920172B1 (enExample) |
| JP (1) | JP6322200B2 (enExample) |
| KR (1) | KR20150084992A (enExample) |
| CN (1) | CN104918940B (enExample) |
| AU (1) | AU2013347539B2 (enExample) |
| BR (1) | BR112015011147A8 (enExample) |
| CA (1) | CA2891013A1 (enExample) |
| MX (1) | MX2015006192A (enExample) |
| RU (1) | RU2661896C2 (enExample) |
| WO (1) | WO2014075393A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0906473A8 (pt) | 2008-01-04 | 2016-02-10 | Intellikine Inc | Certas entidades químicas, composições e métodos |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3145512B1 (en) * | 2014-05-19 | 2019-07-17 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors |
| WO2015188369A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| KR101710127B1 (ko) * | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
| WO2017000125A1 (en) * | 2015-06-29 | 2017-01-05 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2017166104A1 (en) * | 2016-03-30 | 2017-10-05 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| CN108892635A (zh) * | 2018-09-07 | 2018-11-27 | 江苏工程职业技术学院 | 一种西沙必利关键中间体的制备方法 |
| CA3126224A1 (en) * | 2019-01-08 | 2020-07-16 | Corxel Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| WO2024083237A1 (en) * | 2022-10-20 | 2024-04-25 | Impact Therapeutics (Shanghai) , Inc | Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof |
| AR131380A1 (es) | 2022-12-16 | 2025-03-12 | Astrazeneca Ab | Purinas 2,6,9-trisustituidas |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5117830A (en) | 1990-11-08 | 1992-06-02 | Whitby Research, Inc. | Method of determining viability of tissue |
| US5877179A (en) * | 1992-09-29 | 1999-03-02 | The United States Of America As Represented By The Department Of Health And Human Services | Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells |
| RU2112765C1 (ru) * | 1993-02-09 | 1998-06-10 | Дзе Велкам Фаундейшн Лимитед | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРОЯВЛЯЮЩАЯ АКТИВНОСТЬ ПРОТИВ ВИРУСНОЙ ИНФЕКЦИИ И β D-АРАБИНОФУРАНОЗИЛ-2-АМИНО-6-МЕТОКСИ-9Н-ПУРИНЫ |
| US5670501A (en) * | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| AU4157500A (en) * | 1999-03-26 | 2000-10-16 | Astrazeneca Ab | Novel compounds |
| EP1651229A1 (en) | 2003-05-23 | 2006-05-03 | Chiron Corporation | Guanidino-substituted quinazolinone compounds as mc4-r agonists |
| CA2565037A1 (en) * | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
| US7977327B2 (en) | 2004-05-13 | 2011-07-12 | Daiichi Sankyo Company, Limited | Substituted pyrrolidine derivative |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| WO2006099204A1 (en) | 2005-03-11 | 2006-09-21 | Aderis Pharmaceuticals, Inc. | Substituted 9-alkyladenines and the use thereof |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| WO2011075643A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| DE102010011431A1 (de) * | 2009-12-23 | 2011-06-30 | WABCO GmbH, 30453 | Ventileinrichtung für eine Luftfederungsanlage |
| EA201201274A1 (ru) | 2010-03-10 | 2013-04-30 | Инджениум Фармасьютиклз Гмбх | Ингибиторы протеинкиназ |
| US20130096104A1 (en) * | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| AU2011271462A1 (en) * | 2010-06-30 | 2013-01-10 | Amgen Inc. | Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EP2616469B1 (en) | 2010-09-14 | 2016-10-26 | Exelixis, Inc. | 9h-purine compounds as pi3k-delta inhibitors and methods for their manufacture |
| US9273028B2 (en) * | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| CN102838600A (zh) * | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
-
2013
- 2013-11-15 RU RU2015122894A patent/RU2661896C2/ru not_active IP Right Cessation
- 2013-11-15 MX MX2015006192A patent/MX2015006192A/es unknown
- 2013-11-15 CA CA2891013A patent/CA2891013A1/en not_active Abandoned
- 2013-11-15 CN CN201380070631.4A patent/CN104918940B/zh not_active Expired - Fee Related
- 2013-11-15 AU AU2013347539A patent/AU2013347539B2/en not_active Ceased
- 2013-11-15 US US14/443,314 patent/US9938281B2/en active Active
- 2013-11-15 JP JP2015542135A patent/JP6322200B2/ja active Active
- 2013-11-15 WO PCT/CN2013/001395 patent/WO2014075393A1/en not_active Ceased
- 2013-11-15 KR KR1020157015531A patent/KR20150084992A/ko not_active Withdrawn
- 2013-11-15 EP EP13855780.6A patent/EP2920172B1/en active Active
- 2013-11-15 BR BR112015011147A patent/BR112015011147A8/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2920172B1 (en) | 2019-12-25 |
| JP2016502522A (ja) | 2016-01-28 |
| EP2920172A4 (en) | 2016-05-25 |
| CN104918940B (zh) | 2017-03-08 |
| BR112015011147A2 (pt) | 2017-07-11 |
| WO2014075393A1 (en) | 2014-05-22 |
| BR112015011147A8 (pt) | 2019-10-01 |
| AU2013347539B2 (en) | 2017-06-15 |
| CN104918940A (zh) | 2015-09-16 |
| US9938281B2 (en) | 2018-04-10 |
| JP6322200B2 (ja) | 2018-05-09 |
| EP2920172A1 (en) | 2015-09-23 |
| MX2015006192A (es) | 2015-08-10 |
| CA2891013A1 (en) | 2014-05-22 |
| RU2661896C2 (ru) | 2018-07-23 |
| RU2015122894A (ru) | 2017-01-10 |
| AU2013347539A1 (en) | 2015-05-07 |
| US20160207926A1 (en) | 2016-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918940B (zh) | 人磷脂酰肌醇3‑激酶δ的嘌呤抑制剂 | |
| JP6297582B2 (ja) | ヒトホスファチジルイノシトール３−キナーゼデルタのプリン阻害剤 | |
| KR101862493B1 (ko) | Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체 | |
| EP3154976B1 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| WO2011051452A1 (en) | N-containing heteroaryl derivatives as jak3 kinase inhibitors | |
| JP2011529920A (ja) | ピリミジン化合物、組成物及び使用方法 | |
| CN102143746A (zh) | Cdk 调节剂 | |
| WO2012163724A1 (en) | Triazolopyridine compounds | |
| JP2026516206A (ja) | Ｔｙｋ２デグレーダー及びその使用 | |
| CN115873000B (zh) | 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途 | |
| CN121735955A (zh) | 稠合双环类化合物及其制备方法、组合物和应用 | |
| ES2711254T3 (es) | Compuestos de 8-metil-1-fenil-imidazol[1,5-a]pirazina | |
| KR20150130310A (ko) | 야누스 키나제 억제제로서의 같은자리 치환된 시아노에틸피라졸로 피리돈 | |
| HK1222388B (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150611 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20181107 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20191125 |
|
| WITB | Written withdrawal of application |